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(including sharing and discussing it with others). This finding 
suggests the need to further explore the concept of person-
al utility in DTC genomics.  Conclusions: Although this group 
is not representative of the broader population due to both 
their scientific expertise and their willingness to try out a 
controversial new technology, their experiences provide 
valuable insights into the role of personal curiosity and altru-
ism (fostering medical research) as motivations for testing 
and the utility attributed to both. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 For a long time, genetic information for health pur-
poses was obtained in clinical settings only, prescribed by 
a physician on the basis of a specific indication, and with 
pre- and post-test genetic counselling. Since the end 
of the last decade, consumers have been able to obtain 
information about their genetic make-up (traits, ances-
try information, disease susceptibility, etc.) directly 
from commercial companies. These companies are most-
ly located in the USA (e.g. 23andMe) or in Europe (e.g. 
 deCODEme in Iceland and biologis.com in Germany). 
Most companies use single nucleotide polymorphism 
(SNP) genotyping technology to generate their results. 
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 Abstract 
 Aims: This study explores attitudes, motivations and self-re-
ported impact in connection with direct-to-consumer (DTC) 
genomic testing amongst a group of life scientists in Switzer-
land.  Methods: Data were collected through: (1) a self-com-
pletion online questionnaire, and (2) semi-structured quali-
tative interviews. Forty participants completed the ques-
tionnaire and 10 were interviewed.  Results: Curiosity was 
mentioned as the primary reason for undergoing testing, 
while less significance was attributed to receiving actionable 
health information. The opportunity to contribute to re-
search ranked high as a motive for testing. Overall, partici-
pants assessed their experience with the test as positive and 
were willing to recommend it to others. Some reported that 
the testing had an impact on how they view their health, but 
only a third of participants planned on showing the results 
to health practitioners. Participants consistently referred to 
‘fun’ when describing several aspects of the testing experi-
ence. The ‘fun factor’ manifested itself in different phases of 
the process, including the motivation for taking the test, re-
ceiving the information and putting the test results to use 
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Because tests are ordered and results received online, na-
tional borders are regularly crossed.
 In the context of movements such as ‘Quantified Self ’ 
(http://quantifiedself.com/) and other initiatives that 
harness the potential of individually generated and an-
notated data, infrastructures that facilitate individuals’ 
access to their personal genomic information (and pos-
sibly links with other relevant datasets) could reap ben-
efits for personalised medicine  [1, 2] . The debate about 
personal genomics and its role in the emergence of per-
sonalised medicine, however, has been overshadowed by 
the controversy about the risks and benefits of the direct-
to-consumer (DTC) model. The controversy has to a 
large extent become locked in polarised positions  [3] , 
with the central point of critique of the opponents of DTC 
genomics being its low predictive value, as well as its al-
legedly non-existent, or very low,  clinical validity  and clin-
ical utility  of the information provided by DTC genomics. 
Key to this argument is the claim that the information is 
not medically actionable  [4, 5] . Furthermore, opponents 
of DTC genomics argue that such information provided 
without genetic counselling is likely to be misunderstood 
by individuals and thus liable to cause harm, e.g. fostering 
false confidence about not being at risk for a disease or 
causing unwarranted anxiety  [6, 7] . Moreover, worried 
consumers might undergo unnecessary and costly medi-
cal tests, raising health-care costs without any benefit  [8] . 
Concerns about privacy of genomic data have also been 
central to the debate  [9] . On the other side of the divide, 
proponents of DTC genomics argue that such informa-
tion, which is not intended for medical diagnosis, em-
powers consumers. If individuals better understand the 
genomic underpinnings of diseases and traits, they will 
be able to make more informed decisions about their lives 
and their lifestyles. In general, they will be more informed 
participants in, and recipients of, health care. The criti-
cism regarding the questionable validity and utility of the 
information provided by DTC genomics is countered by 
some of the proponents of PG genomics by reference to 
other services that we routinely use in our daily lives and 
that have not spurred significant debate. Such services are 
legal with the proviso of caveat emptor (i.e. the assump-
tion that the customer should know what she is buying), 
and thus, so the argument goes, DTC genomics compa-
nies should be treated in the same manner  [10, 11] . More-
over, despite their agreement on the low clinical utility of 
the information overall, proponents of DTC genomics ar-
gue that some sub-sets of the results provided by compa-
nies do have immediate clinical value: information on 
drug metabolism, for example, could have tangible ben-
efits for the test-taker, e.g., if one knows that one is sensi-
tive to warfarin, one can use this information for dose 
adaptation  [12] .
 While there is merit in most of these arguments, what 
became quickly obvious was the dearth of evidence as to 
why consumers might (or might not) undertake such test-
ing, what such tests mean to them, what impact they have 
on them, and why. Such evidence is, however, critical in 
informing not only the normative arguments about the 
moral acceptability of DTC but also the discussion about 
suitable regulatory approaches.
 Several studies have been conducted to explore these 
questions  [13] . The majority of studies which examined 
attitudes and impact of DTC genomic testing have been 
conducted in the USA  [13] . They concerned early adopt-
ers and focused on motivation for undergoing testing, 
understanding of risk and impact of test results. Some of 
the studies included large samples as parts of ongoing 
projects  [14] . Studies outside the North American conti-
nent include quantitative and qualitative analyses of at-
titudes towards DTC genomics; however, to the best of 
our knowledge, they have not focused on consumers re-
siding outside North America who have already under-
taken DTC testing. One study analysed blog entries post-
ed on DTC genomic websites without distinguishing na-
tional origin  [15] . In sum, there has been no study large 
and robust enough to allow generalisations, especially 
not to publics outside of North America.
 Because commercial genomics first appeared in the 
North American market and operated in English, adver-
tising has probably been most effective in this region as 
well. This assumption is supported by findings that at the 
peak of the media coverage on DTC genomics in the mid-
dle of 2008, only 13% out of 4,050 adults in survey in the 
UK had heard of such services  [16] , indicating that aware-
ness was not very high even in English-speaking coun-
tries outside of North America (or possibly even only cer-
tain areas in the USA). In principle, however, commercial 
genomics services are available to customers all over the 
world. Furthermore, countries (or in the USA, certain 
states) that prohibit providers from offering DTC genetic 
and genomic testing can only do this on their own terri-
tory. Such laws are not binding on consumers of DTC 
services who are physically located in other jurisdictions 
(nevertheless, some DTC genomics companies voluntari-
ly refrain from shipping to areas where DTC genetic and 
genomic testing is prohibited).
 While the first companies offering genomics test-
ing services DTC were 23andMe in Calif., USA, and 
 deCODEme in Iceland, similar companies started ap-
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pearing on the European continent in the early 2010s, 
indicating that the phenomenon of consumer genomics 
might be searching for its niche in the European markets 
(see, for example, biologis.com). Although the future of 
consumer genomics will depend on several factors that 
are impossible to predict  [17] , it is important to start ex-
ploring consumers’ expectations and understanding of, 
and satisfaction with, DTC genomics outside the North 
American context. Not only might there be national and 
cultural differences regarding motivations and percep-
tions, but there are also different regulatory frameworks 
governing such activities within European countries; 
some of them are distinctly different from North Amer-
ica  [18] .
 Our study explores attitudes, motivations and self-re-
ported impact in connection with DTC genomic testing 
amongst a group of life scientists in the Swiss Federal In-
stitute of Technology (ETH) and the University of Zurich 
in Switzerland. Although the study was conducted in 
2011, we use the term  early users to refer to study partici-
pants, because notwithstanding that commercial genom-
ics have been available online since 2007, levels of public 
awareness of the availability of the tests seem to have been 
limited in Switzerland. We base this assumption on the 
limited press coverage of DTC issues over the last few 
years as well as the limited search volume of related key-
words in the Google search engine (we ascertained the 
latter by using GoogleInsights  [19] ). Search volumes 
above the threshold for presentation were only from the 
Zurich area, with 2 spikes: one around 2008 and the sec-
ond after the summer of 2011. The first spike, in 2008, 
was very plausibly caused by the intense media interest in 
the launch of the first DTC genomics companies in the 
USA, which ‘spilled over’, if only on a much smaller scale, 
to continental Europe. The second spike is likely due to a 
well-publicised conference on genomic medicine in Sep-
tember 2011, organised by the Academia Engelberg Foun-
dation whose mission is to foster interdisciplinary dia-
logue about social values and scientific progress  [20] . 
Therefore, it is reasonable to assume that the participants 
in our study group were among the first in the country to 
have undergone DTC genomics testing.
 An additional reason for the ‘slow’ uptake of DTC ge-
nomics testing in Switzerland may be that commercial 
DTC genomics companies, with the exception of the Ger-
man service bio.logis.com which has been available only 
since 2011, operate in English. Although the general level 
of education in Switzerland is high  [21] , and most people 
have a good enough command of English to converse 
about everyday matters, fewer are expected to know En-
glish well enough to engage with the technical and scien-
tific language used by DTC genomics services  [22] .
 All participants in this study reside in Switzerland, a 
country with one of the highest GDP and GDP per capita 
in the world. Both public and private health expenditure 
are comparatively high. Health insurance coverage is 
universal, and life expectancy is amongst the highest 
worldwide. Switzerland has a friendly tax and legal envi-
ronment for business enterprises and a strong biotech 
and life science industry  [23, 24] . The legal environment 
for DTC genomics is less friendly: Swiss law (National 
Law on Genetic Examinations on Humans,  Bundesgesetz 
über genetische Untersuchungen beim Menschen ) prohib-
its genetic and genomic testing that is not prescribed by a 
physician for a medical indication  [25] . Therefore, com-
mercial genomic companies that offer direct-to-consum-
er services are prohibited from doing so from Swiss ter-
ritory. As was discussed above, this law does not prohibit 
that individuals purchase such services abroad. In 2009, 
an expert genetics committee appointed by the Swiss 
Ministry of Health issued a recommendation advising 
the public to refrain from using genetic tests that are 
available online. The main reasons cited by the commit-
tee were the limited clinical validity and utility of such 
tests and concerns about personal data protection  [26] . 
Switzerland already has strict data protection laws.
 Methodology 
 As a part of graduate courses and seminars in molecular ge-
netics at the ETH and the University of Zurich, one of the study 
authors and course instructors (E.H.) introduced the issue of 
commercial genomics (sequencing technology, clinical validity, 
links to personalised medicine) to the audience (researchers and 
students). At the end of each session, members of the audience 
who were interested in better acquainting themselves with geno-
typing were offered the opportunity to register their name with 
the speaker who would then make a bulk order (and bulk ship-
ment) of 23andMe tests. For this purpose, a special educational 
rate was offered by 23andMe (USD 99 instead of the standard 
USD 199 price at the time). A total of 60 people registered. An ad-
ministrator at the Institute of Molecular Biology at the ETH co-
ordinated the order with 23andMe.
 Given the considerable interest in DTC genomics testing 
among the members of the audience, 2 authors of this paper (E.V. 
and E.H.) discussed the possibility of designing a study to explore 
the experience of these test-takers with DTC genomics. Permis-
sion from the research ethics review committee of the canton of 
Zurich was requested and received. We then started data collec-
tion through: (1) a self-completion online questionnaire, and (2) 
semi-structured qualitative interviews carried out in person or by 
phone.
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 Phase 1: Data from 40 Questionnaires 
 Quantitative data: We designed a questionnaire consisting of 
22 questions on the basis of published questionnaires used in sim-
ilar studies  [27, 28] . Questions were intended to explore motiva-
tions for undergoing the test, test-takers’ expectations, experience 
with the testing process and results, and their assessments of the 
impact (in the widest sense) of testing on any aspect of their lives. 
We also asked about specific concerns regarding DTC genomics 
testing and requested some demographic information. We used 
the surveymonkey.com platform to post the questionnaire. One 
of the study authors (E.H.) then distributed the link to all 60 in-
dividuals who had participated in the 23andMe bulk order; this 
took place 2 months after the test kits had been received by test-
takers. An e-mail reminder was sent to the list 3 weeks later. We 
received a total of 40 responses representing a response rate of 
67%. Data were extracted in SPSS Statistics 19.0. Descriptive sta-
tistical analysis was mainly conducted due to the small sample 
size and data format. For some of the questions, where more than 
one answer was possible, new variables were created to assess the 
frequency of each answer. Missing values were excluded from the 
frequencies. Open-ended questions were reviewed for qualitative 
analysis.
 Phase 2: Data from 10 Qualitative Interviews 
 Five months after participants received their 23andMe kits 
(i.e. another 3 months after they had been contacted with the link 
to the questionnaire), another e-mail was sent to the same group 
of individuals with an invitation to participate in a telephone in-
terview to discuss their experience with the test. We received 13 
positive responses; 3 participants were later unable to find time 
for an appointment, which left us with 10 people to interview. In-
terviews were conducted between November and December 2011 
by telephone or in person. They were semi-structured and focused 
on the same thematic areas as the questionnaire. We discussed 
with the informants their motivation for undergoing the test, 
their experience with it, to what extent it matched (or not) their 
expectations, as well as any concerns about testing. Interviews 
lasted between 30 and 45 min. All interviews were audio-record-
ed, transcribed, checked for quality, and imported into a software 
for content analysis (Atlas.ti, 2011, Version 6.2, Berlin, Scientific 
Software Development) based on a grounded theory approach 
 [29, 30] . In parallel, 3 of the authors (E.G., J.S., E.V.) reviewed the 
interview transcripts and developed first level codes. Codes were 
developed on the basis of existing literature and preliminary find-
ings from the quantitative data. First level codes were then col-
lapsed into advanced categories. The frequency of codes was tak-
en into account for the development of categories. Categories were 
analysed for the identification of key themes.
 Results 
 Results from the Questionnaires 
 All those who filled in the online questionnaires had 
studied life science subjects, and most of them held grad-
uate degrees: 8% had a Bachelor’s degree, 40% a Master’s 
degree and 52% had a PhD; 66% of the questionnaire re-
spondents were male. Due to the relatively small size of 
the group, we refrained from asking about age and na-
tionality, to avoid the possibility of identification of some 
participants; however, as the group consisted predomi-
nantly of post-graduate students, we assume that this co-
hort was relatively young, with ages ranging between 25 
and 40 ( table 1 ). Although no data on nationality exists, 
we know that all respondents are residents in Switzer-
land.
 When filling in the questionnaire, respondents were 
asked to choose all motivations for testing that applied 
to them from a list of 4 questions. Questions included 
the general usefulness of genetic information in relation 
to disease susceptibility, including information that can 
lead to preventative steps, curiosity, family history of ge-
netic disease, and the option to give additional reasons. 
It was possible to choose more than one reason. Most 
respondents named curiosity as their main reason for 
undergoing the test. Interestingly, the usefulness of ge-
netic information, especially as a basis for taking mea-
sures to prevent disease, was the second most common 
reason.
 Nine out of 10 respondents described their experience 
with DTC genome testing as positive, and over 7 out of 10 
(73%) said they would recommend this test to a family 
member or a friend. Answers to questions about their sat-
isfaction with the information that they had received in-
dicated, overall, a positive perception. Most respondents 
(64%) said they were likely to share the information with 
their families. When asked whether they deemed it ac-
ceptable that such tests were available online, based on 
their own experience with this service, 6 out of 10 an-
swered affirmatively. More than half of the respondents 
said the results had an impact on how they thought about 
their health (55%), while just over a third disagreed with 
Table 1. D emographics of study participants
Questionnaire, %
(n = 60)
Interviews, %
(n = 10)
Response rate 66.7 (40) 100 (10)
Female 34.2 (13) 70 (7)
Male 65.8 (25)** 30 (3)
Bachelor’s degree 7.9 (3) 0
MSc 39.5 (15) 22.2 (2)
PhD 52.5 (20)** 77.8 (7)*
Mean age – 34.5
Respondents have children – 50 (5)
* 1 missing. ** 2 missing.
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this statement (35%). Less than a third of the participants 
intended to show the results to a health practitioner 
(28%), one-third were undecided (33%), and a slightly 
larger group (38.5%) were not planning to show the re-
sults to a physician.
 More than half of the respondents (55%) were not very 
concerned about privacy and confidentiality issues. 
Among those who did express concern, risks related to 
health insurance coverage were most frequently men-
tioned. When prompted to further specify their con-
cerns, mention was made of third-party companies who 
may access their data and of data security issues.
 Most respondents (66%) also intended to participate in 
research that was offered by the genomics testing com-
pany in a separate section on their website (‘23andWe’). 
Participating in research mostly consists in filling in 
questionnaires about lifestyle, health and selected pheno-
types, thus enabling the company to link this informa-
tion with the test-takers’ SNP data  [31] . Answers to our 
open-ended question about why participants would en-
gage in this type of company-driven research showed that 
most respondents considered such research valuable, ac-
knowledged the need for more data, welcomed an oppor-
tunity to contribute to the common good, and were en-
couraged by the fact that they could choose the type of 
research they would be involved with ( table 2 ).
 Results from the Interviews 
 All 10 participants who agreed to be interviewed had 
studied life science subjects. Seven were female and 3 
were male. Seven had a PhD degree, 2 a Master’s degree 
and were working towards their PhD, and 1 informant 
had both a PhD and an MD degree. The mean age of our 
participants was 35.
 Our qualitative data summarised in  table  3 suggest 
that this group was driven primarily by general curiosity 
to learn new things and to a lesser extent by a goal-orient-
ed desire for personal health information. Seven of our 10 
informants stated curiosity as the main reason for taking 
the test, as exemplified by the following quote: 
 Interviewer: ‘If you had to name one main reason for taking 
the test, what would it be?’ 
 Respondent (R) 2: ‘Of course I was curious to know if there is 
a disease, if there is something you can do [something] about it, 
but for me it was more from a scientific point of view to see what 
would they find out, what they could tell. It was more scientific 
curiosity.’
 Some respondents said explicitly that there was no 
specific question to which they expected the test to pro-
vide an answer. This is how R 5 put it: 
 ‘[…] so there was no specific issue I wanted to know, just gen-
eral overview on how they do it and how differently results are 
presented.’ 
 Other themes that emerged from the analysis of the 
qualitative data on motivation for testing were the ‘fun 
factor’ (mentioned by 7 respondents), the opportunity to 
foster research (half of the respondents) and a distinction 
between scientific curiosity and general curiosity (4 re-
spondents). 
 ‘[It felt like] just a cool idea to do it. Also to do the overall test-
ing with so many people. An overwhelming mass of data. […] I 
thought it was a good idea also because we need more studies, 
more data.’ (R 9) 
 Other respondents echoed this notion, such as R 10: 
 ‘Plain curiosity was the main reason for me […] and the second 
to provide my genome information to society for research pur-
poses.’ 
 The 2 notions – satisfying one’s own curiosity, and 
helping research – were closely connected. This connec-
tion was also reflected in the open-ended questions of the 
survey questionnaire: 
 ‘Phenotype-genotype associations are key to the better under-
standing of genetic information. I feel that my genetic informa-
tion coupled with my [phenotypic] features is something I can 
give to society.’ (This comment was taken from an open-ended 
question in the questionnaire.) 
 Respondents reflecting on the testing experience de-
scribed it as mostly positive, mainly because they found 
that the test satisfied their curiosity. Some indicated that 
they had not high expectations in relation to health infor-
mation when taking the test and ranked the fact that the 
test had satisfied their curiosity and familiarised them 
with commercial genomics services above the impor-
tance of the information that is immediately relevant for 
their health. In the words of R 4, 
 ‘I feel I gained experience in dealing with this sort of probabi-
listic data in relation to my health. It depends on what you mean 
by useful, but if you mean like something I can directly use in re-
lation to medical care, I would say: [it did] little.’ 
 This respondent in fact challenged the common un-
derstanding of the term ‘utility’ when used in the context 
of genetic testing. The term ‘utility’, when used in con-
nection with DTC genomics tests, is typically used syn-
onymously with clinical utility, signifying immediate or 
at least predictable actionability in a clinical context. For 
our respondents, however, utility was much broader: 
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 ‘… and then I was particularly interested in the traits, in fact 
what you can actually see from this. What kind of information 
you can take from your genome about your traits and whether it 
is actually correct. I guess it is just interesting  how much the ge-
nome relates to everything .’ (R 8, emphasis added) 
 None of our respondents disliked anything in particu-
lar in the testing process, with the exception of one who 
felt uncomfortable when she was contacted by other users 
of 23andMe with similar genetic profiles: 
 ‘Someone contacted me and wrote “oh, we have seen your 
background and we could be relatives” or whatever, I don’t re-
member, this I didn’t like at all. So there is no way because we have 
similar backgrounds we may be relatives. […] I blocked this per-
son. But it is not his or her fault; it’s that of 23andMe who allows 
this. But this is not Facebook. Certainly it is an important DNA 
information. If I wanted to have friends, I would just use Facebook 
you know. […] I felt I had less control.’ (R 7)  
Table 2.  Data from the survey questionnaires
Selected
option, %
Did not select
option, %
Reasons for testing*
– Useful in general and specifically to improve health (through prevention, lifestyle changes) 50 50
– Curiosity 88 12
– Family history of genetic diseases 8 92
– Other reasons: (ancestry, drug response information, compare genetic profile with family members) 10 90
Experience with the test*
– The overall experience was positive 90 10
– The overall experience was indifferent 8 92
– The overall experience was negative 2 97
– I would recommend this test to a family member or friend Yes: 73 No: 5
– The results make perfect sense to me and I feel I understand all of it 33 67
– The results make some sense to me and I feel I understand enough of it 61 39
– The results make very little sense to me and I do not feel I understand it 5 95
– The information was presented in a very clear and accessible manner 72 28
– I will need the help of a medical geneticist to understand the results 18 82
– I would like to share the results with my family 64 15
Given the experience with the test, how should such tests be allowed to be accessed by individuals?*
– Over the counter on the Internet 60 40
– By medical prescription only 2 98
– Under supervision/counseling at a health care facility 38 62
Did the information you received impact on how you think of your health?*
– Some impact 55 45
– Serious impact 10 90
– No impact 35 65
– Do you intend to show your results to your doctor? Yes: 28 No: 39
Concerns about DTC testing*
– Serious concerns about privacy and confidentiality 2 98
– Some concerns about privacy and confidentiality 55 45
– No concerns at all 43 57
– Concerns about health insurance 35 65
– Concerns about future employment 25 75
– Concerns use of my data for research that I disagree with 10 90
– Concerns about access by third-party companies, data safety 20 80
– Intention to participate in surveys and research Yes: 66 No: 10
T he table gives information on the percentage of respondents who chose an option (1st column) versus those who did not choose 
it (2nd column), and who agreed with a statement (1st column) versus those who disagreed (2nd column). The remaining percentages 
include those who did not answer or chose ‘I do not know’.
* Multiple options from the list below could be selected.
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 For another informant, in contrast, that very same fea-
ture at the 23andMe website – the ‘Relative Finder’ – 
stood out as one of the most positive aspects of the testing 
process: 
 ‘It was cool […] also to get this feedback from people. For ex-
ample, one lady and one gentleman from the US contacted me say-
ing we might be related, but they said they were not aware of any 
Swiss ancestry. […] but many people with this background emigrat-
ed from an area very close to where my father comes from, in the 
19th century. So we might be relatives. It was really: “oh cool”.’ (R 9) 
 All of those who participated in the qualitative inter-
view felt comfortable about recommending this test to 
others. The reasons for recommending testing to others 
were that based on their experience the test was ‘fun’, it 
satisfied their curiosity and encouraged people to par-
ticipate in research; all of these things were seen as useful 
in one way or another. However, when specifically asked 
to whom they would not recommend the DTC service, 6 
of our informants said that they were reluctant to recom-
mend testing to people who tend to be overly anxious and 
Table 3.  Overview of findings from qualitative data
Themes
(1) Motivation for undertaking DTC testing*
Curiosity –
Scientific curiosity Connected notions of scientific curiosity and research participation, 
data contribution as an investment for the futureParticipation in research
Contributing to scientific advances of the future
Fun Fun factor embedded in other motives
Less interested in health-related results Limited expectations about the value of health-related results
(2) Experience with DTC testing*
Satisfied curiosity –
Satisfied scientific curiosity Positive experience, fun factor, personal utility (for 3 categories)
Gained familiarity with personal genomics
Gained experience with probabilistic data
Relative finder positive –
Not concerned about negative results –
Relative finder negative Privacy concerns
Negative feedback from clinicians about test utility Clinicians skeptical about clinical utility
(3) Recommendation of DTC to others*
Recommend because it is fun to do Recommend for personal utility purposes, importance of research 
participation for future scientific advancesRecommend because it encourages research participation
Recommend to those with genetic literacy Concerns about potential negative reactions (for 3 categories)
Do not recommend to people with anxieties
Recommend to adults only
No medical involvement required Focus on personal utility rather than clinical utility
(4) Self-reported impact of testing*
No lifestyle changes Limited impact (for all 3 categories)
Led healthy lifestyle already
Pharmacogenomic use
(5) Concerns about DTC testing*
Potential privacy breaches Privacy key concern (for 2 categories)
Concern about health insurance
Limited control of online privacy in general Accept online privacy concerns as fact of modern life, concerns not 
prohibitive of participationLittle attention to consent and privacy documents before
participating in testing
* Categories listed below.
Categories which were identified in the response of at least 5 respondents are in italics.
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overly concerned, or to children. A decisive factor in de-
ciding whether to recommend testing or not was the edu-
cational level of the would-be test-taker, in particular 
their level of genetic literacy  [32] .
 Respondents said that the results did not have a sig-
nificant impact on their lives or on their attitude towards 
their health. Most of them described themselves and their 
lifestyles as generally healthy. One informant said that 
some of the pharmagenomic information provided by 
23andMe could be useful in clinical practice, and another 
was able to link results to an existing condition s/he had. 
In relation to discussing results with a physician, most of 
the respondents found this ‘unnecessary’. One informant, 
who had already discussed the results with her physician 
in the context of an existing condition, felt that the physi-
cian paid more attention to her as a result. And R 3 added 
that he was very surprised he got this information, he said, 
because it is usually quite expensive to do this SNP.
 Others who discussed results with a physician did not 
find it helpful, particularly due to the physicians’ negative 
reactions: 
 ‘The interesting thing is, I told my doctor I had taken this 
23andMe test [in relation to pharmacogenomics] and he really 
thought this is not a serious thing.’ (R 6)
 ‘Actually a friend of ours is a medical doctor, and I discussed 
it with him, and he thought it was crazy altogether. It is complete-
ly useless for their practice, they think.’ (R 10) 
 Like our questionnaire respondents, half of the infor-
mants acknowledged potential privacy concerns, but did 
not consider them prohibitive. They mentioned potential 
risks such as insurance companies obtaining or demand-
ing access to such data, but they referred to this as an ob-
stacle to be overcome. Participants acknowledged that 
there was limited control of privacy in every online envi-
ronment, but none of them considered this a significant 
enough reason to prohibit the use of online genomic ser-
vices: 
 ‘What I didn’t like was the co-funding of 23andMe with 
Google. We are giving away too much responsibility to databases.
[…] If you put it all together, bank information, genomics infor-
mation, our communication, consumption and all that together, 
you might have a lot to lose.’ (R 10)
 ‘I don’t think I am 100% safe about [data] protection, if people 
are really curious about someone’s data, they will find a thousand 
ways to get the information …’ (R 3)
 ‘I am not concerned. Only my genetic data [alone] don’t tell 
that much. If people want to know something […], they can find 
it another way.’ (R 5)
 ‘Well, I am not so paranoid. [It is not that bad] if someone in 
the world knows that I am susceptible to developing diabetes …’ 
(R 6) 
 The opportunity to participate in research, and the 
value of research in general, were prominent themes with 
all informants. In particular, the need for large data sets 
to catalyse progress in understanding the human genome 
was mentioned as one of the key reasons for their par-
ticipation. Informants said that 23andMe gave them an 
opportunity they otherwise would not have had to help 
advance research. Individual contributions to research 
were discussed in terms of ‘investments’ in the future, 
with returns being the acceleration of medical discovery 
and better medicine. Perhaps also partly for this reason, 
most respondents said they had not read the informed 
consent document carefully. When asked why they had 
not, they said that they had a ‘habit’ of signing up to 
things online after taking just a quick look at the terms of 
conditions, and that they did not have any concerns about 
the research process. The demographics of the group 
might also further explain their ease with online plat-
forms of any kind. Participants were aware of the privacy 
risks and the limited control of personal data once they 
were online; yet they seemed to accept this as a fact of 
modern life. It is notable that most of our interview par-
ticipants had not spent much time reading the consent 
and privacy policies of 23andMe, and none of them was 
aware of the Swiss expert committees’ recommendation 
against online genetic testing.
 Discussion 
 Participants both in the online questionnaire and in 
the interviews attributed limited significance to the ex-
tent to which test results were immediately relevant to 
their health. While there was interest in what kind of 
health information the test would yield, and how this in-
formation would be presented, even this ‘professional’ 
curiosity in health (given that almost all of our partici-
pants had life science degrees) was not mentioned as the 
decisive reason for taking the test. The driving factor for 
our informants was a more general – i.e. not health-fo-
cused – curiosity ranging from wanting to see ‘what it 
looks like’, to more specific technical aspects of how raw 
data are presented, how risk probability is derived in rela-
tion to published genome-wide association studies and 
what kind of research projects are available. Some re-
spondents explicitly drew a distinction between scientif-
ic curiosity (or scientific interest) and general curiosity. 
Curiosity features as a motive in most other studies with 
users of DTC genomics testing services conducted to 
date. However, in those other studies, the main motiva-
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tion that participants stated for taking the test was the 
desire to learn about the degree to which they were at risk 
for developing particular conditions  [13] . What we ob-
served in our respondents, in contrast, was a much more 
general curiosity pertaining to technical aspects of the 
service. Health information was only the medium, not 
the target, of their interest.
 Participants consistently referred to ‘fun’ when de-
scribing several aspects of the testing experience. The ‘fun 
factor’ manifested itself in different phases of the process, 
including the motivation for taking the test (participants 
thought of it as a fun thing to do), receiving the informa-
tion (the actual experience was positive and pleasant) and 
putting the test results to use (either to share with friends 
and family or for research). The fact that most partici-
pants felt confident about evaluating the health informa-
tion they received may partly explain why their focus was 
on enjoying other personal uses of the process, such as 
research participation. What was striking in the group we 
studied was that participants did not express worries 
about seeing results that could cause anxieties; this, how-
ever, may have to do with the professional background of 
virtually all the participants, who thus felt confident 
enough to understand and interpret the results. Moreover, 
it is likely that those who were concerned about the con-
sequences of receiving SNP-based risk information did 
not sign up to order a test in the first place. In addition, a 
question arises as to whether the marketing messages of 
DTC companies inviting consumers to be in charge of 
their health might have been less appealing for our par-
ticipants living outside the North American culture.
 As highlighted earlier, the opportunity to participate 
in research was seen by the majority of our interview par-
ticipants as an important aspect of the testing experience. 
For some participants, it was the main reason to get test-
ed, while those who mentioned curiosity as the main mo-
tivation for taking the test saw research participation as 
an added benefit of the testing process; it enabled them to 
make a useful contribution to science and society. An al-
truistic motivation matching the profile of the ‘health in-
formation altruist’  [33] was coupled with the knowledge 
and conviction that large data sets are needed in order to 
successfully pursue genomic research. Moreover, the fact 
that many in our study group were professionally in-
volved in research undoubtedly contributes to explaining 
this phenomenon.
 In relation to the predictive power of the results, one 
of the themes that emerged in interactions with our study 
group was that of future utility. When talking about the 
information they received, many participants referred to 
the value that the results could have at a later stage. Ac-
tionability, therefore, was not understood to be imme-
diate, but it expanded into the mid- or even long-term 
future. This extended also to the utility that our par-
ticipants attributed to their participation in 23andMe’s 
research endeavors promoted on the website. Getting in-
volved in the present was seen as important in light of 
potential future benefits. This may help to explain (a) why 
our participants would recommend testing to family and 
friends; and (b) why they were comfortable with online 
access of testing without involvement on the part of med-
ical professionals. While the concern about genetic liter-
acy of lay people and its importance in interpreting re-
sults was appropriately raised, the overall moral impera-
tive to foster scientific progress prevailed.
 Exploring Personal Utility 
 Satisfaction of their (general or scientific) curiosity, 
and satisfaction/contentment from research participa-
tion, are both dimensions of personal utility, an aspect of 
personal genomics that has been insufficiently explored. 
Foster et al.  [34] highlighted the need to expand the con-
cept of utility in personal genomics beyond the narrow 
sense of clinical utility in order to encompass valuable 
uses that genomic information may have for the individ-
ual. Lesko et al.  [35] further argued that the notion of 
clinical utility should be expanded to include personal 
utility. But even in these proposals, personal utility is im-
plicitly assumed to relate to some future health goal(s). 
For example, individuals may use the (not immediately 
clinically actionable) information to change their lifestyle 
in order to improve their health.
 Although these are steps in the right direction, these 
proposals do not go far enough  [36, 37] . What has emerged 
from our data is that facets of personal utility not direct-
ly linked to personal health outcomes played a prominent 
role in explaining why at least our study group engaged 
with DTC genomic testing. Our volunteers spoke of the 
test results – and in fact the entire testing experience – as 
being useful. What kind of utility is it that they were talk-
ing about, and why did it come up in connection with 
DTC genomics?
 Other commentators have already alluded to the ‘rec-
reational’ aspect of personal genomics and the interest of 
enthusiastic early adopters in participating in the ‘ge-
nomic revolution’  [38] . But such aspects have also been 
described as dangerous because they ‘confuse entertain-
ment with useful medical information’  [39] . However, if 
users of DTC genomics services find the experience use-
ful, in whatever way, on what basis should their claim to 
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utility be overruled? In other words, in the context of test-
ing that does not convey results with immediate clinical 
relevance, why does utility need to be defined in clinical 
terms? It is true that most of the existing DTC companies 
market their services as health-related; yet health is much 
broader than clinical medicine. Doing things that feel 
pleasant, that are ‘fun’, that make one engage with the 
genetic and lifestyle-related factors involved in health 
and disease, are related to the broader sense of well-being.
 Limitations 
 This group is not representative of the broader popula-
tion due to both their scientific expertise and their will-
ingness to try out a new technology surrounded by con-
troversy. As with early adopters of other technologies this 
group represents a group of ethical and cognitive ‘pio-
neers’  [40] because they are engaged with situations that 
both raise and address ethical and scientific questions not 
previously addressed in these ways. Their reasons for us-
ing DTC genomics and their attitude towards the process 
and its outcomes provide valuable insights into the moral 
and psychological background against which such tech-
nologies will be deployed.
 Thus, although the specific characteristics of our par-
ticipants prevent us from generalising our findings to 
wider groups, these same specific characteristics allow us 
to explore aspects of personal genomics which are likely 
to become of wider relevance. An example here is the no-
tion of personal utility, which has been mentioned, but 
not yet conceptualised in the literature. Several questions 
remain unanswered and call for more research: would 
‘fun’ and ‘curiosity’ be equally important motivators for 
other groups as they were for the group of people we stud-
ied? Are our findings specific to Switzerland and/or Ger-
man-speaking regions? Larger empirical studies are 
 needed in order to ascertain whether cultural differences 
in particular play a role in perceptions about DTC ge-
nomics and their moral acceptability.
 Conclusion 
 In sum, we argue that the notion of personal utility 
requires further elaboration in order to take into account 
a broader spectrum of values, not merely clinical out-
comes. Our study group, although being a very particular 
group due to the context in which they were recruited and 
their life science expertise, provided valuable insights 
into the alignment of personal curiosity and altruistic 
motivations (fostering medical research) and the utility 
attributed to both. A broader and more nuanced under-
standing of personal utility that makes room for a variety 
of aspects, including non-clinical aspects, needs to be de-
veloped. This will in turn enable us to better understand 
and evaluate the reasons that different groups have for 
engaging not only with DTC genetic testing but also with 
online-mediated health tools in general. 
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